European Urology Oncology A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer  Niranjan J. Sathianathen, Fernando Alarid-Escudero, Karen M. Kuntz, Nathan Lawrentschuk, Damien M. Bolton, Declan G. Murphy, Simon P. Kim, Badrinath R. Konety  European Urology Oncology  DOI: 10.1016/j.euo.2019.01.004 Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 1 Cost-effectiveness acceptability curve showing the probability that a treatment represents the most cost-effective strategy at a particular willingness-to-pay threshold. QALY=quality-adjusted life year. European Urology Oncology DOI: (10.1016/j.euo.2019.01.004) Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 2 Incremental cost-effectiveness scatter plot of 5000 simulations demonstrating a low to moderate probability of abiraterone acetate (AA) plus androgen deprivation therapy being cost-effective even at willingness-to-pay thresholds beyond those that are commonly accepted. A point has to be to the right and below the willingness-to-pay threshold line to be cost-effective. European Urology Oncology DOI: (10.1016/j.euo.2019.01.004) Copyright © 2019 European Association of Urology Terms and Conditions